Anti-angiogenic Ophthalmic Agents Market

The Anti-angiogenic Ophthalmic Agents Market size was valued at USD 4.24 Billion in 2025 and the total Anti-angiogenic Ophthalmic Agents revenue is expected to grow at a CAGR of 3.89% from 2025 to 2032, reaching nearly USD 5.53 Billion by 2032.

Anti-angiogenic Ophthalmic Agents Market: Overview

The Anti-angiogenic ophthalmic agents act as antagonists against the vascular endothelial growth factor (VEGF). When retinal pigment cells become ischemic and dry up VEGF stimulates generation of new blood vessels by a process called neovascularization. If new blood vessels are not generated properly, leakage occurs in retina, which leads to vision loss. Angiogenesis plays an important role in chronic inflammation and fibrosis, tumor growth and vascularization of ischemic tissue.
To Know About The Research Methodology :- Request Free Sample Report

Anti-angiogenic Ophthalmic Agents Market: Dynamics

Anti-angiogenic Ophthalmic Agents Market Trends

Gene Therapy Pipeline Driving Long-Acting Anti-VEGF Therapies

The market for Anti-angiogenic Ophthalmic Agents is undergoing a revolution towards anti-VEGF agents based on gene therapy, which seek to address the issue of frequent intravitreal injections associated with traditional therapies. By using adeno-associated viral (AAV) vector, along with other emerging lentiviral and CRISPR/Cas technology, this therapy allows for the constant expression of anti-VEGF protein by the retinal cells after just one administration in order to ensure prolonged treatment of retinal diseases such as nAMD and DME. This growing pipeline includes RGX-314, 4D-150, ADVM-022, LX102, SKG0106, RRG001, EXG102-031, FT-003, KH631, KH658, ABI-110, HG202, BD311, and LX109.

• According to Investigative Ophthalmology & Visual Science (IOVS), there are more than 14 anti-VEGF gene therapy candidates that are in development phases I–III. Preliminary clinical data indicate that the gene therapy candidates reduce the number of required anti-VEGF injections in a year to 80-92% and almost 50% of patients do not require any injections for a year or even longer, hence the huge potential of gene therapy to revolutionize retinal disease treatment.

Anti-angiogenic Ophthalmic Agents Market Driver

Increase in Prevalence Rate of Retinal Vascular Disease

The increasing prevalence rate of retinal vascular disease including wet AMD, DR, DME, and RVO Are driving the market for anti-angiogenic ophthalmics in the coming years. it caused by abnormal function of VEGF angiogenesis and vascular permeability, the anti-VEGF drugs will have higher preference among all the other drugs. As the prevalence rate of chronic conditions like diabetes will increase owing to the aging population, the number of patients who will need these drugs for a long time will also increase and thus there will be an increase in demand for the drugs.

• According to IAPB, there are almost 200 million people suffering from AMD globally, this number is expected to increase to 288 million by 2040.
•  according to IDF Diabetes Atlas 2025, There are almost 589 million people having diabetes globally, Out of these people, 1 in every 3 persons has diabetic retinopathy (DR).

Anti-angiogenic Ophthalmic Agents Market Restraints

High Cost of Treatment and Repeatable Intravitreal Injections

The high cost of anti-angiogenic treatments for eye diseases, along with frequent intravitreal injections, is continuing to hamper the Anti-angiogenic Ophthalmic Agents Market. Anti-angiogenic drugs used in the treatment of ophthalmic conditions need regular doses of medication for continued efficacy, which is why the total cost of the treatment becomes quite expensive for patients and health-care providers. The need for repeatable visits to clinics and possible side effects from injections, along with the lack of coverage in some developing nations, decreases adherence to treatment and its availability. Additionally, the high price of branded biologic products makes their application in certain areas difficult.

• According to the American Academy of Ophthalmology (AAO), patients who undergo treatment with anti-VEGF agents for retinal disorders are usually required to receive 6-12 intravitreal injections per year.

Anti-angiogenic Ophthalmic Agents Market Opportunities

Growing Application of Long-Acting Anti-Angiogenic Ophthalmic Drugs

Development of long-acting anti-angiogenic ophthalmic drugs becomes an excellent growth opportunity for the Anti-angiogenic Ophthalmic Agents Market. In most cases, current anti-VEGF therapy is associated with multiple intravitreal injections which are rather troublesome both for patients and health care providers. New types of innovative therapies, such as Susvimo® (ranibizumab injection with ocular implant), can decrease the need in injections without lowering the efficacy. Thus, the application of anti-angiogenic ophthalmic agents may be expected to increase due to development of extended-release biological products and implantable drug-delivery systems.

• Genentech approves the use of Susvimo (ranibizumab injection) in order to treat wet AMD, DME, and DR in adult patients who were responsive to previous intravitreal VEGF inhibitors treatment.
  According to the U.S. Food and Drug Administration (FDA), Susvimo is the first refillable ocular implant for delivering ranibizumab continuously.

Anti-angiogenic Ophthalmic Agents Market Key Development 

• On June 18, 2025, The American Academy of Ophthalmology (AAO) highlighted the growing adoption of long-acting anti-angiogenic ophthalmic therapies, including aflibercept 8 mg (Eylea HD) and faricimab (Vabysmo). These next-generation therapies enable longer treatment intervals while maintaining visual outcomes in patients with retinal diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). By reducing the need for frequent intravitreal injections, they help improve patient adherence, lessen the treatment burden, and enhance the overall management of chronic retinal disorders.
• November 25, 2025 ,The American Academy of Ophthalmology (AAO) reaffirmed the effectiveness of anti-angiogenic ophthalmic therapies in managing retinal vascular diseases. According to the organization, these therapies improve vision in approximately one-third of patients, while about 90% of patients experience stabilization of vision, helping prevent further vision loss. AAO also emphasized that anti-angiogenic therapies remain the standard of care for treating wet age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR), and retinal vein occlusion (RVO) due to their proven safety and long-term clinical benefits.

Segment Analysis

By Drug Class

The VEGF Antibody Fragments sub-segment is expected to account for 35-40% market share in the global Anti-angiogenic Ophthalmic Agents Market in 2025. The factors attributing to the leadership of the VEGF antibody fragments sub-segment include the availability of drugs like Lucentis (ranibizumab) and others for retinal vascular diseases. It is due to high efficiency, safety, and effectiveness in treating various eye diseases like wet AMD, DME, DR, and RVO. In addition, approvals and reimbursement are other reasons for the leadership of the sub-segment.
The Bispecific Antibodies sub-segment is projected to witness the highest CAGR during the forecast period. The development of bispecific antibodies like faricimab (Vabysmo), which target VEGF-A and Ang-2 concurrently, increases the duration of treatment without impacting vision and treatment frequency. Innovations in biological agents would help the growth of the sub-segment during the forecast period.

By Disease Indication

The Neovascular (Wet) Age-related Macular Degeneration (nAMD) segment held the largest market share of approximately 40–45% in 2025. The high prevalence of age-related retinal degeneration among the elderly population, coupled with the availability of multiple approved anti-VEGF therapies, has made nAMD the leading indication. Increasing awareness, improved diagnostic technologies such as optical coherence tomography (OCT), and routine retinal screening programs continue to support early diagnosis and treatment initiation.

The Diabetic Macular Edema (DME) segment is projected to witness the fastest growth due to the rising global prevalence of diabetes. Increasing incidence of diabetic retinopathy and expanding access to ophthalmic care in emerging economies are driving demand for anti-angiogenic therapies. Longer-acting biologics and sustained drug delivery systems are also improving treatment adherence in diabetic patients.

Regional Insights

North America accounted for largest market share in the year 2025, followed by Europe.

Increasing prevalence of eye related disorders like AMD, cataract, glaucoma, diabetic retinopathy, diabetic macular edema and dry eye disorders in the region and high availability of commercialized Anti-angiogenic Ophthalmic Agents are some of the driving factors for market in the region. Age-related macular degeneration (AMD) complications are the leading cause of severe vision loss among people aged 65 years and over in the United States and many western countries. For instance, in 2021, Bausch + Lomb launched Ocuvite Eye Performance vitamin supplements in the U.S. in order to meet the increasing needs of U.S. consumers. Besides this, Europe held the second largest share owing to increasing prevalence of myopic choroidal neovascularization in the region.

Asia Pacific is expected to witness fastest growth.

Increasing prevalence of diabetes and other eye related disorders in Asian countries with rising geriatric population pool who are more susceptible in acquiring these vision impairments will contribute to the market growth.

The report also helps in understanding Global Anti-angiogenic Ophthalmic Agents Market dynamics, structure by analyzing the market segments and project the Global Anti-angiogenic Ophthalmic Agents Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Anti-angiogenic Ophthalmic Agents Market make the report investor’s guide.

Anti-angiogenic Ophthalmic Agents Market Scope: Inquire before buying

Anti-angiogenic Ophthalmic Agents Market, by Region

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)

Anti-angiogenic Ophthalmic Agents Market Key Players

1. Gilead Sciences, Inc.
2. Eyetech Inc.
3. Becton, Dickinson and Company
4. Regeneron Pharmaceuticals, Inc.
5. Genentech, Inc.
6. Novartis AG
7. Allergan plc
8. Bayer AG
9. Santen Pharmaceutical Co., Ltd.
10.Shanghai Pharmaceuticals
11.Johnson & Johnson
12.Pfizer
13.Sun Pharma
14.Otsuka Pharmaceutical Co. Ltd
15.Daiichi Sankyo
16.ERC Labs
17.Medicom Health care
18.Implandata ophthalmic products GmbH
19.The Geuder Group, MORCHER GmbH
20.Novamedika

Frequently Asked Questions:

1. Which region has the largest share in Global Anti-angiogenic Ophthalmic Agents Market?
Ans: North America region held the highest share in 2025.

2. What is the growth rate of Global Anti-angiogenic Ophthalmic Agents Market?
Ans: The Global Anti-angiogenic Ophthalmic Agents Market is growing at a CAGR of 3.89% during forecasting period 2026-2032.

3. What is scope of the Global Anti-angiogenic Ophthalmic Agents Market report?
Ans: Global Anti-angiogenic Ophthalmic Agents Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Global Market?
Ans: The important key players in the Global Market are – Gilead Sciences, Inc., Eyetech Inc., Becton, Dickinson and Company, Regeneron Pharmaceuticals, Inc., Genentech, Inc., Novartis AG, Allergan plc, Bayer AG, Santen Pharmaceutical Co., Ltd., Shanghai Pharmaceuticals, Johnson & Johnson, Pfizer, Sun Pharma, Otsuka Pharmaceutical Co. Ltd, Daiichi Sankyo, ERC Labs, and Medicom Health care.

5. What is the study period of this Market?
Ans: The Global Anti-angiogenic Ophthalmic Agents Market is studied from 2025 to 2032.